[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fW2efy1XXUCqFI994Zn5R_PyK6vhQqgyYvRt9et7xcQ4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":71,"rows":78},"University of Bern",[4],207,false,60,4,587036,13,191,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Smoking Cessation",12,{"name":18,"count":19},"Healthy",9,{"name":21,"count":22},"Mild Cognitive Impairment",7,{"name":24,"count":22},"Exposure to Man-made Visible Light",{"name":26,"count":27},"Alzheimer Disease",6,{"name":29,"count":30},"Childhood Cancer",5,{"name":32,"count":30},"Dental Implant Failed",{"name":34,"count":30},"Suicidal Ideation",[36,41,46,51,56,61,66],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06630585","GIP\u002FGLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes","2026-06","Tirzepatide",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07401628","In-Vehicle Real-Time Cannabis Influenced Driving Detection","2026-06-19","Cannabis",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06120855","Study on Regulated Cannabis Sales in Pharmacies","2026-09-30","Regulated cannabis from authorized pharmacies",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06227065","Precise Neoadjuvant Chemoresection of Low Grade NMIBC","2026-10","Epirubicin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07013682","PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy","2026-12-24","PRF as adjunct to non-surgical mechanical debridement",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06384209","The Friendship Bench Plus Trial","2027-12-28","Fluoxetine",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04715542","Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity","2028-08","Stibium metallicum praeparatum 6x",[72,73,74,75,76,77],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[79,103,126,153,171,189,207,231,249,271,295,313,338,356,382,410,435,453,479,497,522,547,578,596,621,648],{"intervention":40,"totalTrials":80,"cells":81},1,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":99,"NA":101},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":84},[],{"trials":90,"activeCount":80,"soonestReadout":39},[91],{"nctId":37,"briefTitle":38,"status":92,"phases":93,"primaryCompletion":39,"completion":39,"start":94,"enrollment":95,"conditions":96,"interventions":98},"RECRUITING",[75],"2025-02-14",42,[97],"Type 1 Diabetes (T1D)",[40],{"trials":100,"activeCount":84},[],{"trials":102,"activeCount":84},[],{"intervention":70,"totalTrials":80,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":122,"NA":124},{"trials":106,"activeCount":84},[],{"trials":108,"activeCount":84},[],{"trials":110,"activeCount":84},[],{"trials":112,"activeCount":80,"soonestReadout":69},[113],{"nctId":67,"briefTitle":68,"status":114,"phases":115,"primaryCompletion":69,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NOT_YET_RECRUITING",[75],"2029-08","2026-08",120,[120],"Chemotherapy Induced Peripheral Neuropathy (CIPN)",[70],{"trials":123,"activeCount":84},[],{"trials":125,"activeCount":84},[],{"intervention":55,"totalTrials":80,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":129,"activeCount":84},[],{"trials":131,"activeCount":84},[],{"trials":133,"activeCount":80,"soonestReadout":54},[134],{"nctId":52,"briefTitle":53,"status":114,"phases":135,"primaryCompletion":54,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":143},[74],"2029-10","2024-10",28,[140,141,142],"Bladder Cancer","Non-muscle Invasive Bladder Cancer","Low-risk",[55,144,145,146],"Mitomycin","Gemcitabine","Docetaxel",{"trials":148,"activeCount":84},[],{"trials":150,"activeCount":84},[],{"trials":152,"activeCount":84},[],{"intervention":144,"totalTrials":80,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":156,"activeCount":84},[],{"trials":158,"activeCount":84},[],{"trials":160,"activeCount":80,"soonestReadout":54},[161],{"nctId":52,"briefTitle":53,"status":114,"phases":162,"primaryCompletion":54,"completion":136,"start":137,"enrollment":138,"conditions":163,"interventions":164},[74],[140,141,142],[55,144,145,146],{"trials":166,"activeCount":84},[],{"trials":168,"activeCount":84},[],{"trials":170,"activeCount":84},[],{"intervention":145,"totalTrials":80,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":174,"activeCount":84},[],{"trials":176,"activeCount":84},[],{"trials":178,"activeCount":80,"soonestReadout":54},[179],{"nctId":52,"briefTitle":53,"status":114,"phases":180,"primaryCompletion":54,"completion":136,"start":137,"enrollment":138,"conditions":181,"interventions":182},[74],[140,141,142],[55,144,145,146],{"trials":184,"activeCount":84},[],{"trials":186,"activeCount":84},[],{"trials":188,"activeCount":84},[],{"intervention":146,"totalTrials":80,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":192,"activeCount":84},[],{"trials":194,"activeCount":84},[],{"trials":196,"activeCount":80,"soonestReadout":54},[197],{"nctId":52,"briefTitle":53,"status":114,"phases":198,"primaryCompletion":54,"completion":136,"start":137,"enrollment":138,"conditions":199,"interventions":200},[74],[140,141,142],[55,144,145,146],{"trials":202,"activeCount":84},[],{"trials":204,"activeCount":84},[],{"trials":206,"activeCount":84},[],{"intervention":60,"totalTrials":80,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":210,"activeCount":84},[],{"trials":212,"activeCount":84},[],{"trials":214,"activeCount":84},[],{"trials":216,"activeCount":84},[],{"trials":218,"activeCount":84},[],{"trials":220,"activeCount":80,"soonestReadout":59},[221],{"nctId":57,"briefTitle":58,"status":92,"phases":222,"primaryCompletion":59,"completion":59,"start":223,"enrollment":224,"conditions":225,"interventions":229},[77],"2025-05-01",20,[226,227,228],"Periodontitis","Periodontal Inflammation","Periodontal Attachment Loss",[60,230],"Control, non-surgical mechanical debridement alone",{"intervention":230,"totalTrials":80,"cells":232},{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":234,"activeCount":84},[],{"trials":236,"activeCount":84},[],{"trials":238,"activeCount":84},[],{"trials":240,"activeCount":84},[],{"trials":242,"activeCount":84},[],{"trials":244,"activeCount":80,"soonestReadout":59},[245],{"nctId":57,"briefTitle":58,"status":92,"phases":246,"primaryCompletion":59,"completion":59,"start":223,"enrollment":224,"conditions":247,"interventions":248},[77],[226,227,228],[60,230],{"intervention":45,"totalTrials":80,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":261},{"trials":252,"activeCount":84},[],{"trials":254,"activeCount":84},[],{"trials":256,"activeCount":84},[],{"trials":258,"activeCount":84},[],{"trials":260,"activeCount":84},[],{"trials":262,"activeCount":80,"soonestReadout":44},[263],{"nctId":42,"briefTitle":43,"status":92,"phases":264,"primaryCompletion":44,"completion":44,"start":265,"enrollment":266,"conditions":267,"interventions":270},[77],"2026-01-05",45,[268,269],"Driving Under the Influence","Cannabis-impaired Driving",[45],{"intervention":65,"totalTrials":80,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":274,"activeCount":84},[],{"trials":276,"activeCount":84},[],{"trials":278,"activeCount":84},[],{"trials":280,"activeCount":84},[],{"trials":282,"activeCount":84},[],{"trials":284,"activeCount":80,"soonestReadout":64},[285],{"nctId":62,"briefTitle":63,"status":92,"phases":286,"primaryCompletion":64,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":293},[77],"2028-02-28","2025-06-26",296,[291,292],"Major Depressive Disorder","Severe Depressive Episode Without Psychotic Symptoms",[65,294],"Sertraline Pill",{"intervention":294,"totalTrials":80,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":305,"NA":307},{"trials":298,"activeCount":84},[],{"trials":300,"activeCount":84},[],{"trials":302,"activeCount":84},[],{"trials":304,"activeCount":84},[],{"trials":306,"activeCount":84},[],{"trials":308,"activeCount":80,"soonestReadout":64},[309],{"nctId":62,"briefTitle":63,"status":92,"phases":310,"primaryCompletion":64,"completion":287,"start":288,"enrollment":289,"conditions":311,"interventions":312},[77],[291,292],[65,294],{"intervention":50,"totalTrials":80,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":316,"activeCount":84},[],{"trials":318,"activeCount":84},[],{"trials":320,"activeCount":84},[],{"trials":322,"activeCount":84},[],{"trials":324,"activeCount":84},[],{"trials":326,"activeCount":80,"soonestReadout":49},[327],{"nctId":47,"briefTitle":48,"status":328,"phases":329,"primaryCompletion":49,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":336},"ACTIVE_NOT_RECRUITING",[77],"2029-12-31","2024-03-11",1177,[334,45,335],"Marijuana Smoking","Cannabis Use",[50,337],"Cannabis from the illicit market",{"intervention":337,"totalTrials":80,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":84},[],{"trials":343,"activeCount":84},[],{"trials":345,"activeCount":84},[],{"trials":347,"activeCount":84},[],{"trials":349,"activeCount":84},[],{"trials":351,"activeCount":80,"soonestReadout":49},[352],{"nctId":47,"briefTitle":48,"status":328,"phases":353,"primaryCompletion":49,"completion":330,"start":331,"enrollment":332,"conditions":354,"interventions":355},[77],[334,45,335],[50,337],{"intervention":357,"totalTrials":80,"cells":358},"Naltrexone",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":380},{"trials":360,"activeCount":84},[],{"trials":362,"activeCount":84},[],{"trials":364,"activeCount":84},[],{"trials":366,"activeCount":84},[],{"trials":368,"activeCount":84},[369],{"nctId":370,"briefTitle":371,"status":372,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT02792140","The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams","COMPLETED",[76],"2016-11","2016-03",32,[378],"Neuroscience of Dreaming, Healthy",[357],{"trials":381,"activeCount":84},[],{"intervention":383,"totalTrials":80,"cells":384},"Euphrasia Officinalis Preparation",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":406,"NA":408},{"trials":386,"activeCount":84},[],{"trials":388,"activeCount":84},[],{"trials":390,"activeCount":84},[],{"trials":392,"activeCount":84},[393],{"nctId":394,"briefTitle":395,"status":372,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":405},"NCT04122300","Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct",[75],"2016-12-12","2016-12-16","2011-05-22",84,[402,403,404],"Congenita Nasolacrimal Duct Obstruction","Preterm Neonates","Ocular Discharge",[383],{"trials":407,"activeCount":84},[],{"trials":409,"activeCount":84},[],{"intervention":411,"totalTrials":80,"cells":412},"High ribavirin dose",{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":414,"activeCount":84},[],{"trials":416,"activeCount":84},[],{"trials":418,"activeCount":84},[419],{"nctId":420,"briefTitle":421,"status":372,"phases":422,"primaryCompletion":423,"completion":423,"start":424,"enrollment":376,"conditions":425,"interventions":427},"NCT00944684","High Dose Ribavirin in the Treatment of Chronic Hepatitis C",[74],"2011-04","2007-11",[426],"Chronic Hepatitis C",[411,428],"Standard ribavirin dose",{"trials":430,"activeCount":84},[],{"trials":432,"activeCount":84},[],{"trials":434,"activeCount":84},[],{"intervention":428,"totalTrials":80,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":438,"activeCount":84},[],{"trials":440,"activeCount":84},[],{"trials":442,"activeCount":84},[443],{"nctId":420,"briefTitle":421,"status":372,"phases":444,"primaryCompletion":423,"completion":423,"start":424,"enrollment":376,"conditions":445,"interventions":446},[74],[426],[411,428],{"trials":448,"activeCount":84},[],{"trials":450,"activeCount":84},[],{"trials":452,"activeCount":84},[],{"intervention":454,"totalTrials":80,"cells":455},"Urtica comp. gel",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":457,"activeCount":84},[],{"trials":459,"activeCount":84},[],{"trials":461,"activeCount":84},[462],{"nctId":463,"briefTitle":464,"status":372,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT03494205","Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis",[74],"2022-02-10","2018-05-02",31,[470],"Radiation Dermatitis",[454,472],"institutional standard skin care \"Excipial-Hydrolotion\"",{"trials":474,"activeCount":84},[],{"trials":476,"activeCount":84},[],{"trials":478,"activeCount":84},[],{"intervention":472,"totalTrials":80,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":84},[],{"trials":484,"activeCount":84},[],{"trials":486,"activeCount":84},[487],{"nctId":463,"briefTitle":464,"status":372,"phases":488,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":489,"interventions":490},[74],[470],[454,472],{"trials":492,"activeCount":84},[],{"trials":494,"activeCount":84},[],{"trials":496,"activeCount":84},[],{"intervention":498,"totalTrials":80,"cells":499},"Sorafenib",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":501,"activeCount":84},[],{"trials":503,"activeCount":84},[504],{"nctId":505,"briefTitle":506,"status":372,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT00478374","Sorafenib With TACE to Treat Hepatocellular Carcinoma",[73],"2009-01","2007-05",21,[512],"Hepatocellular Carcinoma",[498],{"trials":515,"activeCount":84},[],{"trials":517,"activeCount":84},[],{"trials":519,"activeCount":84},[],{"trials":521,"activeCount":84},[],{"intervention":523,"totalTrials":80,"cells":524},"Rituximab",{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":526,"activeCount":84},[],{"trials":528,"activeCount":84},[],{"trials":530,"activeCount":84},[],{"trials":532,"activeCount":84},[],{"trials":534,"activeCount":84},[],{"trials":536,"activeCount":84},[537],{"nctId":538,"briefTitle":539,"status":372,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":27,"conditions":544,"interventions":546},"NCT00267826","Immunopharmacological Effects of Rituximab in Atopic Dermatitis",[77],"2006-06","2006-12","2005-12",[545],"Dermatitis, Atopic",[523],{"intervention":548,"totalTrials":80,"cells":549},"AMPT\u002F Demser",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":551,"activeCount":84},[],{"trials":553,"activeCount":84},[],{"trials":555,"activeCount":84},[],{"trials":557,"activeCount":84},[],{"trials":559,"activeCount":84},[],{"trials":561,"activeCount":84},[562],{"nctId":563,"briefTitle":564,"status":565,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":8,"conditions":570,"interventions":576},"NCT02179814","Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls","SUSPENDED",[77],"2019-05","2022-05","2012-02-20",[571,572,573,574,575],"Bulimia Nervosa","Eating Disorders","Dopamine","Reward","Catechol-O-methyltransferase",[548,577],"Diphenhydramine",{"intervention":577,"totalTrials":80,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":581,"activeCount":84},[],{"trials":583,"activeCount":84},[],{"trials":585,"activeCount":84},[],{"trials":587,"activeCount":84},[],{"trials":589,"activeCount":84},[],{"trials":591,"activeCount":84},[592],{"nctId":563,"briefTitle":564,"status":565,"phases":593,"primaryCompletion":567,"completion":568,"start":569,"enrollment":8,"conditions":594,"interventions":595},[77],[571,572,573,574,575],[548,577],{"intervention":597,"totalTrials":80,"cells":598},"Dexamethason Helvepharm ®",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":600,"activeCount":84},[],{"trials":602,"activeCount":84},[],{"trials":604,"activeCount":84},[],{"trials":606,"activeCount":84},[],{"trials":608,"activeCount":84},[],{"trials":610,"activeCount":84},[611],{"nctId":612,"briefTitle":613,"status":372,"phases":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT00619086","Steroid Before Thyroidectomy",[77],"2007-06","2005-11",72,[619],"Thyroid Surgery for Benign Disease",[597],{"intervention":622,"totalTrials":80,"cells":623},"with CoQ10 spray application",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":625,"activeCount":84},[],{"trials":627,"activeCount":84},[],{"trials":629,"activeCount":84},[],{"trials":631,"activeCount":84},[],{"trials":633,"activeCount":84},[],{"trials":635,"activeCount":84},[636],{"nctId":637,"briefTitle":638,"status":372,"phases":639,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT04487652","Ubiquinone (Coenzyme Q10) Application After Gingival Recession Coverage",[77],"2022-08-31","2023-01-31","2020-09-01",30,[645],"Gingival Recession",[622,647],"with placebo spray application",{"intervention":647,"totalTrials":80,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":651,"activeCount":84},[],{"trials":653,"activeCount":84},[],{"trials":655,"activeCount":84},[],{"trials":657,"activeCount":84},[],{"trials":659,"activeCount":84},[],{"trials":661,"activeCount":84},[662],{"nctId":637,"briefTitle":638,"status":372,"phases":663,"primaryCompletion":640,"completion":641,"start":642,"enrollment":643,"conditions":664,"interventions":665},[77],[645],[622,647]]